A biotechnology company developing stem cell therapies to treat neurodegenerative diseases
Our proprietary technology converts mesenchymal stem cells into NurOwn®, a biological drug delivery system designed to support damaged neurons
NurOwn® cells dampen the immune system and secrete growth factors that help damaged neurons survive.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
January 11, 2019BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
January 3, 2019BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week
December 27, 2018BrainStorm Issues 2018 Letter to Shareholders
BrainStorm is proceeding with a randomized, double-blind, placebo-controlled multi-dose Phase 3 trial that is being conducted at multiple U.S. sites.
For more information on enrollment, contact one of the participating clinical trial sites.
Additional information can be found on clinicaltrials.gov under identifier (NCT number): NCT03280056.